A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Diabetes

• Publication date

  1999-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2337/DIABETES.48.12.2414PMID 10580431
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment

  2005cited by this paper
• Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors

  2004cited by this paper
• Troglitazone Lowers Islet Fat and Restores Beta Cell Function of Zucker Diabetic Fatty Rats*

  1998cited by this paper
• Metabolic Effects of Troglitazone Monotherapy in Type 2 Diabetes Mellitus

  1998cited by this paper
• Regulation of skeletal muscle hexokinase II by insulin in nondiabetic and NIDDM subjects.

  1998cited by this paper
• Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

  1998cited by this paper
• Effect of troglitazone on B cell function, insulin sensitivity, and glycemic control in subjects with type 2 diabetes mellitus.

  1998cited by this paper
• United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.

  1998cited by this paper
• Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

  1998cited by this paper
• Effects of Metformin on Lactate Uptake and Gluconeogenesis in the Perfused Rat Liver

  1997cited by this paper
• The Role of Fatty Acids in Mediating the Effects of Peripheral Insulin on Hepatic Glucose Production in the Conscious Dog

  1997cited by this paper
• Thiazolidinediones.

  1997cited by this paper
• Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance.

  1997cited by this paper
• Effects of Nonesterified Fatty Acids on Glucose Metabolism After Glucose Ingestion

  1997cited by this paper
• Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.

  1997cited by this paper
• Metformin Potentiates Glucose-Stimulated Insulin Secretion

  1996cited by this paper
• Causal linkage between insulin suppression of lipolysis and suppression of liver glucose output in dogs.

  1996cited by this paper
• Hyperinsulinemia as an independent risk factor for ischemic heart disease.

  1996cited by this paper
• Cellular and Molecular Mechanisms of Non-Insulin Dependent Diabetes Mellitus

  1996cited by this paper
• Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes

  1996cited by this paper
• Effect of metformin on various aspects of glucose, insulin and lipid metabolism in patients with non-insulin-dependent diabetes mellitus with varying degrees of hyperglycemia.

  1995cited by this paper
• The insulin-sparing effect of metformin in insulin-treated diabetic patients.

  1995cited by this paper
• Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

  1995cited by this paper
• Metabolic effects of metformin in non-insulin-dependent diabetes mellitus.

  1995cited by this paper
• Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.

  1994cited by this paper
• Acute Antihyperglycemic Mechanisms of Metformin in NIDDM: Evidence for Suppression of Lipid Oxidation and Hepatic Glucose Production

  1994cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• Intensive Conventional Insulin Therapy for Type II Diabetes: Metabolic effects during a 6-mo outpatient trial

  1993cited by this paper
• Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM Subjects

  1992cited by this paper
• Beta-cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion.

  1992cited by this paper
• Oral Hypoglycaemic Agents: The First Thirty Years

  1992cited by this paper
• Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects.

  1991cited by this paper
• The insulin sparing effect of metformin in insulin-treated diabetic patients.

  1991cited by this paper
• Effect of Metformin on Carbohydrate and Lipoprotein Metabolism in NIDDM Patients

  1990cited by this paper
• Postreceptor Effects of Sulfonylurea on Skeletal Muscle Glycogen Synthase Activity in Type II Diabetic Patients

  1989cited by this paper
• Metformin improves peripheral but not hepatic insulin action in obese patients with type II diabetes.

  1989cited by this paper
• Metformin potentiates B-cell response to high glucose: an in vitro study on isolated perfused pancreas from normal rats.

  1989cited by this paper
• Inhibition of hepatic gluconeogenesis by metformin. Synergism with insulin.

  1988cited by this paper
• Insulin Therapy Induces Antiatherogenic Changes of Serum Lipoproteins in Noninsulin‐Dependent Diabetes

  1988cited by this paper
• Clinical benefits and mechanisms of a sustained response to intermittent insulin therapy in type 2 diabetic patients with secondary drug failure.

  1988cited by this paper
• Mechanism of Metformin Action in Non-Insulin-Dependent Diabetes

  1987cited by this paper
• Estimation of Endogenous Glucose Production During Hyperinsulinemic-Euglycemic Glucose Clamps: Comparison of Unlabeled and Labeled Exogenous Glucose Infusates

  1987cited by this paper
• Effects of Weight Loss on Mechanisms of Hyperglycemia in Obese Non-Insulin-Dependent Diabetes Mellitus

  1986cited by this paper
• The Effect of Insulin Treatment on Insulin Secretion and Insulin Action in Type II Diabetes Mellitus

  1985cited by this paper
• Insulin Therapy in Obese, Non-insulin-dependent Diabetes Induces Improvements in Insulin Action and Secretion that Are Maintained for Two Weeks After Insulin Withdrawal

  1984cited by this paper
• Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group.

  1979cited by this paper
• Glucose clamp technique: a method for quantifying insulin secretion and resistance.

  1979cited by this paper
• Characterization of Seven C-peptide Antisera

  1978cited by this paper
• Use of polyethylene glycol to separate free and antibody-bound peptide hormones in radioimmunoassays.

  1971cited by this paper
• INFLUENCES OF GLUCOSE LOADING AND OF INJECTED INSULIN ON HEPATIC GLUCOSE OUTPUT *

  1959cited by this paper

• Insulin Requirement Profiles of Short-Term Continuous Subcutaneous Insulin Infusion Therapy in Patients With Type 2 Diabetic Nephropathy

  2025cites this paper
• Impact of the timing of metformin administration on glycaemic and glucagon-like peptide-1 responses to intraduodenal glucose infusion in type 2 diabetes: a double-blind, randomised, placebo-controlled, crossover study

  2024cites this paper
• Metformin: A Promising Alternative to Alleviate the Gastrointestinal Side Effects Associated

  2023cites this paper
• Trends in glycemic control in patients with insulin therapy compared with non-insulin or no drugs in type 2 diabetes in Japan: a long-term view of real-world treatment between 2002 and 2018 (JDDM 66)

  2022cites this paper
• The Mechanism of Action of Biguanides: New Answers to a Complex Question

  2022cites this paper
• Treatment of Diabetes Mellitus: General Goals and Clinical Practice Management

  2022cites this paper
• Hypoglycemic and in vitro antioxidant activities of Stereospermum kunthianum stem bark hydromethanol extract

  2022influential citation
• The effects of hydroxychloroquine on insulin sensitivity, insulin clearance and inflammation in insulin‐resistant adults: A randomized trial

  2021cites this paper
• A New Understanding of Metformin

  2021cites this paper
• Cellular and Molecular Mechanisms of Metformin Action

  2020cites this paper
• The role of polysaccharides from natural resources to design oral insulin micro- and nanoparticles intended for the treatment of Diabetes mellitus: A review.

  2020cites this paper
• Study protocol: a pragmatic, stepped-wedge trial of tailored support for implementing social determinants of health documentation/action in community health centers, with realist evaluation

  2019cites this paper
• Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: A randomized, double‐blind, placebo‐controlled, multicenter trial: The MASTERS trial

  2019cites this paper
• Metformin and its gastrointestinal problems: A review

  2018cites this paper
• Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future

  2018cites this paper
• Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes

  2018cites this paper
• Young onset type 2 diabetic patients might be more sensitive to metformin compared to late onset type 2 diabetic patients

  2017cites this paper
• Oral Antihyperglycemic Therapy for Type 2 Diabetes

  2017cites this paper
• Clinical Audit on the Provision of Diabetes Care in the Primary Care Setting by United Nations Relief and Works Agency for Palestine Refugees in the Near East (UNRWA)

  2015cites this paper
• Addition of sitagliptin or metformin to insulin monotherapy improves blood glucose control via different effects on insulin and glucagon secretion in hyperglycemic Japanese patients with type 2 diabetes.

  2015cites this paper
• WITHDRAWN: Metformin monotherapy for type 2 diabetes mellitus.

  2015cites this paper
• Phytochemical Screening, Hypoglycemic and Antihyperglycemic Effect of Flavonoids from the Leaves of Algerian Olea europaea L. in Normal and Alloxan-Induced Diabetic Rats

  2015cites this paper
• Progressive β Cell Failure in Type 2 Diabetes Mellitus: Microvascular Pancreatic Isletopathy?

  2015cites this paper
• Metformin improves glucose effectiveness, not insulin sensitivity: predicting treatment response in women with polycystic ovary syndrome in an open-label, interventional study.

  2014cites this paper
• Insulin therapy in type 2 diabetes : Initiation, impact on liver fat, role of combination therapy with glitazones or glindes

  2014cites this paper
• The ‘collateral benefits‘ of noninsulin therapies for Type 2 diabetes

  2013cites this paper
• Comparison of Metformin and Insulin Monotherapy with Combined Metformin and Insulin Therapy in Patients of Type 2 Diabetes with HbA1c > 7%.

  2011cites this paper
• Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

  2010cites this paper
• Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROactive19).

  2010cites this paper
• The pharmacologic basis for the treatment of endocrinopathic laminitis.

  2010cites this paper
• Effect of two starting insulin regimens in patients with type II diabetes not controlled on a combination of oral antihyperglycemic medications.

  2009cites this paper
• Tratamiento combinado de la diabetes tipo 2

  2009cites this paper
• Scientific Review Oral Antihyperglycemic Therapy for Type 2 Diabetes

  2009cites this paper
• The AMP-regulated kinase family: enigmatic targets for diabetes therapy.

  2009influential citation
• Rosiglitazone reduces liver fat and insulin requirements and improves hepatic insulin sensitivity and glycemic control in patients with type 2 diabetes requiring high insulin doses.

  2008cites this paper
• LIVER FAT IN THE METABOLIC SYNDROME AND TYPE 2 DIABETES

  2008cites this paper
• Combined Therapy With Insulin Plus Oral Agents: Is There Any Advantage?

  2008cites this paper
• Dual PPAR α/γ Agonists: Promises and Pitfalls in Type 2 Diabetes

  2007cites this paper
• Oral antidiabetic agents as cardiovascular drugs

  2007cites this paper
• Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes

  2007cites this paper
• Effects of insulin therapy on liver fat content and hepatic insulin sensitivity in patients with type 2 diabetes.

  2007cites this paper
• Low-dose rosiglitazone in patients with insulin-requiring type 2 diabetes.

  2007cites this paper
• Comparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetes.

  2006cites this paper
• Effects of metformin and thiazolidinediones on suppression of hepatic glucose production and stimulation of glucose uptake in type 2 diabetes: a systematic review

  2006cites this paper
• Rationale, design, and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial.

  2006cites this paper
• Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

  2006cites this paper
• Efficacy of glimepiride in patients with poorly controlled insulin-treated type 2 diabetes mellitus.

  2005cites this paper
• Medicaid managed care: disparities in the use of thiazolidinediones compared with metformin.

  2005cites this paper
• Does metformin decrease blood pressure in patients with Type 2 diabetes intensively treated with insulin?

  2005cites this paper
• COMISSÃO DE REDAÇÃO

  2005cites this paper
• Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus

  2005cites this paper
• An overview of the beneficial cardiovascular effects of thiazolidinediones

  2005cites this paper
• Metformin monotherapy for type 2 diabetes mellitus.

  2005cites this paper
• Thiazolidinediones and Insulin

  2005cites this paper
• Sociedade Brasileira de Cardiologia Brazilian Society of Cardiology Conselho Editorial Editorial Board

  2005cites this paper
• Oral Agents for Type 2 Diabetes: An Update

  2005cites this paper
• Durability of Glycemic Control: A Feature of the Thiazolidinediones

  2004influential citation
• A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus.

  2004cites this paper
• Managing obesity and glycemic control in insulin-using patients: clinical relevance and practice recommendations.

  2004cites this paper
• Improved glycemic control without weight gain using triple therapy in type 2 diabetes.

  2004cites this paper
• Oral antidiabetic agents: 2004.

  2004cites this paper
• Pioglitazone is Effective Therapy for Elderly Patients with Type 2 Diabetes Mellitus

  2004cites this paper
• The stepwise approach to the management of type 2 diabetes.

  2004cites this paper
• Treatment of insulin resistance in diabetes mellitus.

  2004cites this paper
• Sulfonylureas: Basic Aspects and Clinical Uses

  2004cites this paper
• Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus.

  2004cites this paper
• Cost-effective management of hyperglycemia in patients with type 2 diabetes using oral agents.

  2004cites this paper
• Combined Thiazolidinedione-Insulin Therapy

  2004cites this paper
• Drug therapy of diabetes in the elderly.

  2003cites this paper
• Efficacy of Sulfonylureas with Insulin in Type 2 Diabetes Mellitus

  2003cites this paper
• ROSIGLITAZONE: POTENTIAL BENEFICIAL IMPACT ON CARDIOVASCULAR DISEASE

  2003cites this paper
• Beneficial effects of triple drug combination of pioglitazone with glibenclamide and metformin in type 2 diabetes mellitus patients on insulin therapy.

  2003cites this paper
• Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis.

  2003cites this paper
• Metformin: new understandings, new uses.

  2003cites this paper
• Clinical use of thiazolidinediones: recommendations.

  2003cites this paper
• Insulin, glucagon, and hypoglycemic drugs

  2003cites this paper
• Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

  2002cites this paper
• Oral antihyperglycemic therapy for type 2 diabetes: scientific review.

  2002cites this paper
• Scientific Review and Clinical Applications

  2002cites this paper
• Thiazolidinediones in the treatment of managed care patients with type 2 diabetes.

  2002cites this paper
• [Combined treatment of type 2 diabetes].

  2002cites this paper
• Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes

  2002cites this paper
• Treating hyperglycemia in type 2 diabetes: new goals and strategies.

  2002cites this paper
• Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus.

  2002cites this paper
• Type 2 diabetes therapy

  2002cites this paper
• Acarbose for type 2 diabetes prevention.

  2002cites this paper
• Muscle uridine diphosphate-hexosamines do not decrease despite correction of hyperglycemia-induced insulin resistance in type 2 diabetes.

  2002cites this paper
• The underuse of insulin therapy in North America

  2002cites this paper
• [Treatment of diabetes mellitus: general goals, and clinical practice management].

  2002cites this paper
• Hepatic glucose production: therapeutic target in type 2 diabetes?

  2002cites this paper
• Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes.

  2002cites this paper
• Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and troglitazone in type 2 diabetes.

  2002cites this paper
• Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and β‐cell dysfunction

  2002cites this paper
• Timely addition of insulin to oral therapy for type 2 diabetes.

  2002cites this paper
• Tratamiento de la diabetes mellitus: objetivos generales y manejo en la práctica clínica

  2002cites this paper
• Rationale for and role of thiazolidinediones in type 2 diabetes mellitus.

  2002cites this paper
• Management of Rosiglitazone-Induced Edema: Two Case Reports and a Review of the Literature

  2002cites this paper
• Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.

  2002cites this paper
• Cerivastatin improves insulin sensitivity and insulin secretion in early-state obese type 2 diabetes.

  2002cites this paper
• The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients.

  2002cites this paper